Jean-Denis Dubois, Ph.D., is a Director, Investments, of the Fonds de Solidarité des Travailleurs du Québec (F.T.Q.)("Le Fonds") in the biotechnology and health sectors. Prior to joining Le Fonds, Dr. Dubois was Associate Director of Medical Research at the Laval University Medical Center (CHUL) Research Center, where he played a key role in the implementation of GLP for pre-clinical studies to be submitted to the FDA and to Health Canada as well as in the implementation of GCP for Phase I and Phase II clinical studies of new drugs; and was responsible for the enforcement of GLP and GCP standards. He was appointed Professor and Director of the Science and Technology Department at the Université de Québec Télé-Université with responsibility for program development. He worked as a researcher and journalist for the Radio-Canada television science program, Science-Réalité and then for Radio-Québecs series, Nova. He helped establish CHUL International, is the founder of Opération Enfant Soleil and has been involved in public financings for research purposes. Dr. Dubois holds a B.A., a B.Sc. in Biology (Physiology), a M.Sc. (Experimental Medicine) and a Ph.D. in Endocrinology.
Pierre Hochuli joined PolyTechnos in 1999 as a Managing Partner. Previously, Mr. Hochuli spent 23 years with Monsanto, where he was President International, Corporate Executive Vice-President and member of Monsantos Executive Board. He also served as President of Monsanto Growth Enterprises, VP for Corporate Strategy/Planning, VP and General Manager of Monsantos agriculture R&D/New Product Division and held several general management and marketing positions inEurope,South Americaand theU.S. He was a board member of industry associations, such as EuropaBio, and the U.S.-China Business Council. He currently serves as a board member of several high-tech companies. Mr. Hochuli holds a MBA from the Heriot-Watt University in Edinburghand is a graduate of the Harvard Business Schools Advanced Management Program. He also holds a diploma from the Basel School of Business and Economics (KHS).
Gratien Lavoie is a Director, Investments, of Le Fonds as well as a member of several professional associations in Québec. Mr. Lavoies career has included senior management level positions with a number of global companies, including President of Outils Coupants Tivoly (Québec), General Trust, several economic development agencies and Le Fonds and he has also held seats on the board of several companies. He was involved with several educational institutions as Director of Students and as Professor. Throughout his career, he has been involved in the restructuring and reorganization processes of several corporations where he has been involved in a consulting capacity. Mr. Lavoie holds a Masters Degree in Business from Concordia University and has completed diplomas in education, administration, economics and international business development.
Frankie TanSiew Teck is Senior Vice President of Vertex Management (II) Private Ltd., a private equity fund of the Vertex Group. Mr. Tan is involved in the Europe-based investments and is on the boards of a number of companies in which the Vertex Group has equity interests. Prior to joining Vertex Group in 1996, Mr. Tan worked for 11 years with Singapore Technologies Marine, where he held various sales, marketing and business development positions, including Vice President, Marketing & Business Development. He started his career with the Republic of Singapore Navy, where he worked six years as a Marine Technical Officer. Mr. Tan holds a Master of Science Degree in Financial Management from the University of London. He is also a graduate of the Association of Chartered Certified Accountants, UK, and is a member of the Institute of Certified Public Accountants of Singapore.
Ronald M. Urvater has been President and sole shareholder of Capital Partners, an investment banking company that specializes in the funding of early-stage medical and technology companies and provides funding as a principal for companies seeking first round financing. Mr. Urvater is also Managing Director of Aurora Capital LLC, an investment banking company specializing in the private financing of private and public life sciences companies. He was a founder and served as a director from 1985 to 1997 of T Cell Sciences Inc. (now AVANT Immunotherapeutics, Inc.) Mr. Urvater received a Bachelor of Science from the University of Pennsylvania and a MBA from the Columbia School of Business.